BT8009-100: A phase I/II study of novel bicyclic peptide and MMAE conjugate BT8009 in patients (pts) with advanced malignancies associated with nectin-4 expression, including urothelial cancer (UC).

Capucine Baldini, Vincent Goldschmidt, Irene Brana, Bernard Doger, Antoine Italiano, Sophie Cousin, Gerald Steven Falchook, Andrea Necchi, Oscar Reig, Louise Carter, Elisa Fontana, Loic Verlingue, Sebastien Hazard, Amy Dickson, Cong Xu, Hongmei Xu, Rajiv Sharma, Dominic Smethurst, Meredith McKean

Research output: Contribution to conference › Abstract › peer-review

Fingerprint

Dive into the research topics of 'BT8009-100: A phase I/II study of novel bicyclic peptide and MMAE conjugate BT8009 in patients (pts) with advanced malignancies associated with nectin-4 expression, including urothelial cancer (UC).'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science